Management of chronic hepatitis B in children

An unresolved issue

Claudia Della Corte, Valerio Nobili, Donatella Comparcola, Francesca Cainelli, Sandro Vento

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Although a rather benign course of chronic hepatitis B virus (HBV) infection during childhood has been described, 3-5% and 0.01-0.03% of chronic carriers develop cirrhosis or hepatocellular carcinoma before adulthood. Considering the whole lifetime, the risk of hepatocellular carcinoma rises to 9-24% and the incidence of cirrhosis to 2-3% per year. The aim of this article is to review the current knowledge regarding the natural history and treatment of chronic hepatitis B in children and to focus on critical aspects and unresolved questions in the management of childhood HBV infection. A literature search was carried out on MEDLINE, EMBASE, and Web of Science for articles published in English in peer-reviewed journals from January 1980 to February 2013. The search terms used included "Hepatitis B virus infection," "children," "HBV," "interferon," "lamivudine," "adefovir," "entecavir," and "tenofovir." Articles resulting from these searches and relevant references cited in the articles retrieved were reviewed. The current goals of therapy are to suppress viral replication, reduce liver inflammation, and reverse liver fibrosis. Therapeutic options for children are currently limited, and the risk for viral resistance to current and future therapies is a particular concern. Based on the data available at this time, it is the consensus of the panel that it is not appropriate to treat children in the immune-tolerant phase or in the inactive carrier state. For children in the immune-active or reactivation phases, liver histology can help guide treatment decisions. Outside of clinical trials, interferon is the agent of choice in most cases; currently, available nucleoside analogs are secondary therapies.

Original languageEnglish
Pages (from-to)912-919
Number of pages8
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume29
Issue number5
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Chronic Hepatitis B
Hepatitis B virus
Virus Diseases
Tenofovir
Interferons
Hepatocellular Carcinoma
Fibrosis
Therapeutics
Carrier State
Lamivudine
Liver
Natural History
Nucleosides
MEDLINE
Liver Cirrhosis
Histology
Clinical Trials
Inflammation
Incidence

Keywords

  • Antiviral therapy
  • Children
  • HBV infection

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Management of chronic hepatitis B in children : An unresolved issue. / Della Corte, Claudia; Nobili, Valerio; Comparcola, Donatella; Cainelli, Francesca; Vento, Sandro.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 29, No. 5, 2014, p. 912-919.

Research output: Contribution to journalReview article

Della Corte, Claudia ; Nobili, Valerio ; Comparcola, Donatella ; Cainelli, Francesca ; Vento, Sandro. / Management of chronic hepatitis B in children : An unresolved issue. In: Journal of Gastroenterology and Hepatology (Australia). 2014 ; Vol. 29, No. 5. pp. 912-919.
@article{ce0fa47a2a6b4b9099637f8d2b95ab4d,
title = "Management of chronic hepatitis B in children: An unresolved issue",
abstract = "Although a rather benign course of chronic hepatitis B virus (HBV) infection during childhood has been described, 3-5{\%} and 0.01-0.03{\%} of chronic carriers develop cirrhosis or hepatocellular carcinoma before adulthood. Considering the whole lifetime, the risk of hepatocellular carcinoma rises to 9-24{\%} and the incidence of cirrhosis to 2-3{\%} per year. The aim of this article is to review the current knowledge regarding the natural history and treatment of chronic hepatitis B in children and to focus on critical aspects and unresolved questions in the management of childhood HBV infection. A literature search was carried out on MEDLINE, EMBASE, and Web of Science for articles published in English in peer-reviewed journals from January 1980 to February 2013. The search terms used included {"}Hepatitis B virus infection,{"} {"}children,{"} {"}HBV,{"} {"}interferon,{"} {"}lamivudine,{"} {"}adefovir,{"} {"}entecavir,{"} and {"}tenofovir.{"} Articles resulting from these searches and relevant references cited in the articles retrieved were reviewed. The current goals of therapy are to suppress viral replication, reduce liver inflammation, and reverse liver fibrosis. Therapeutic options for children are currently limited, and the risk for viral resistance to current and future therapies is a particular concern. Based on the data available at this time, it is the consensus of the panel that it is not appropriate to treat children in the immune-tolerant phase or in the inactive carrier state. For children in the immune-active or reactivation phases, liver histology can help guide treatment decisions. Outside of clinical trials, interferon is the agent of choice in most cases; currently, available nucleoside analogs are secondary therapies.",
keywords = "Antiviral therapy, Children, HBV infection",
author = "{Della Corte}, Claudia and Valerio Nobili and Donatella Comparcola and Francesca Cainelli and Sandro Vento",
year = "2014",
doi = "10.1111/jgh.12550",
language = "English",
volume = "29",
pages = "912--919",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley Blackwell",
number = "5",

}

TY - JOUR

T1 - Management of chronic hepatitis B in children

T2 - An unresolved issue

AU - Della Corte, Claudia

AU - Nobili, Valerio

AU - Comparcola, Donatella

AU - Cainelli, Francesca

AU - Vento, Sandro

PY - 2014

Y1 - 2014

N2 - Although a rather benign course of chronic hepatitis B virus (HBV) infection during childhood has been described, 3-5% and 0.01-0.03% of chronic carriers develop cirrhosis or hepatocellular carcinoma before adulthood. Considering the whole lifetime, the risk of hepatocellular carcinoma rises to 9-24% and the incidence of cirrhosis to 2-3% per year. The aim of this article is to review the current knowledge regarding the natural history and treatment of chronic hepatitis B in children and to focus on critical aspects and unresolved questions in the management of childhood HBV infection. A literature search was carried out on MEDLINE, EMBASE, and Web of Science for articles published in English in peer-reviewed journals from January 1980 to February 2013. The search terms used included "Hepatitis B virus infection," "children," "HBV," "interferon," "lamivudine," "adefovir," "entecavir," and "tenofovir." Articles resulting from these searches and relevant references cited in the articles retrieved were reviewed. The current goals of therapy are to suppress viral replication, reduce liver inflammation, and reverse liver fibrosis. Therapeutic options for children are currently limited, and the risk for viral resistance to current and future therapies is a particular concern. Based on the data available at this time, it is the consensus of the panel that it is not appropriate to treat children in the immune-tolerant phase or in the inactive carrier state. For children in the immune-active or reactivation phases, liver histology can help guide treatment decisions. Outside of clinical trials, interferon is the agent of choice in most cases; currently, available nucleoside analogs are secondary therapies.

AB - Although a rather benign course of chronic hepatitis B virus (HBV) infection during childhood has been described, 3-5% and 0.01-0.03% of chronic carriers develop cirrhosis or hepatocellular carcinoma before adulthood. Considering the whole lifetime, the risk of hepatocellular carcinoma rises to 9-24% and the incidence of cirrhosis to 2-3% per year. The aim of this article is to review the current knowledge regarding the natural history and treatment of chronic hepatitis B in children and to focus on critical aspects and unresolved questions in the management of childhood HBV infection. A literature search was carried out on MEDLINE, EMBASE, and Web of Science for articles published in English in peer-reviewed journals from January 1980 to February 2013. The search terms used included "Hepatitis B virus infection," "children," "HBV," "interferon," "lamivudine," "adefovir," "entecavir," and "tenofovir." Articles resulting from these searches and relevant references cited in the articles retrieved were reviewed. The current goals of therapy are to suppress viral replication, reduce liver inflammation, and reverse liver fibrosis. Therapeutic options for children are currently limited, and the risk for viral resistance to current and future therapies is a particular concern. Based on the data available at this time, it is the consensus of the panel that it is not appropriate to treat children in the immune-tolerant phase or in the inactive carrier state. For children in the immune-active or reactivation phases, liver histology can help guide treatment decisions. Outside of clinical trials, interferon is the agent of choice in most cases; currently, available nucleoside analogs are secondary therapies.

KW - Antiviral therapy

KW - Children

KW - HBV infection

UR - http://www.scopus.com/inward/record.url?scp=84898897207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898897207&partnerID=8YFLogxK

U2 - 10.1111/jgh.12550

DO - 10.1111/jgh.12550

M3 - Review article

VL - 29

SP - 912

EP - 919

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 5

ER -